Ethic Inc. Buys 1,753 Shares of DexCom, Inc. $DXCM

Ethic Inc. raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 3.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 49,205 shares of the medical device company’s stock after purchasing an additional 1,753 shares during the quarter. Ethic Inc.’s holdings in DexCom were worth $4,248,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DXCM. Nuveen LLC bought a new stake in DexCom in the first quarter valued at approximately $554,893,000. Jennison Associates LLC raised its holdings in shares of DexCom by 37.7% during the first quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company’s stock valued at $718,632,000 after acquiring an additional 2,879,489 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of DexCom by 171.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company’s stock valued at $218,175,000 after acquiring an additional 2,015,971 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of DexCom by 2,371.4% during the first quarter. Federated Hermes Inc. now owns 1,994,732 shares of the medical device company’s stock valued at $136,220,000 after acquiring an additional 1,914,019 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of DexCom by 22.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after acquiring an additional 1,868,241 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, Director Kyle Malady sold 667 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the sale, the director directly owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael Jon Brown sold 500 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares in the company, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,849 shares of company stock valued at $564,733. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 10th. Truist Financial decreased their target price on DexCom from $102.00 to $94.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Weiss Ratings restated a “hold (c-)” rating on shares of DexCom in a report on Wednesday, October 8th. Argus assumed coverage on DexCom in a report on Thursday, August 21st. They set a “buy” rating and a $100.00 target price for the company. Finally, Citigroup decreased their target price on DexCom from $105.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $96.40.

DexCom Price Performance

DXCM opened at $71.06 on Friday. The stock has a fifty day simple moving average of $72.59 and a two-hundred day simple moving average of $77.71. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The company has a market cap of $27.87 billion, a price-to-earnings ratio of 49.35, a price-to-earnings-growth ratio of 1.49 and a beta of 1.47. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. Research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.